Cargando…
Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
INTRODUCTION: Severe hypoglycemia is a medical emergency that must be treated promptly in order to prevent complications or death in a patient. Patients who have been diagnosed with Type 1 diabetes and treated with insulin have the potential to experience a severe hypoglycemia episode, or low blood...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473428/ https://www.ncbi.nlm.nih.gov/pubmed/37663896 http://dx.doi.org/10.2147/PPA.S325865 |
_version_ | 1785100271420964864 |
---|---|
author | Schaumleffel, Carol |
author_facet | Schaumleffel, Carol |
author_sort | Schaumleffel, Carol |
collection | PubMed |
description | INTRODUCTION: Severe hypoglycemia is a medical emergency that must be treated promptly in order to prevent complications or death in a patient. Patients who have been diagnosed with Type 1 diabetes and treated with insulin have the potential to experience a severe hypoglycemia episode, or low blood sugar. When a patient is experiencing severe hypoglycemia, it is imperative for this patient to receive glucose quickly. However, patients who are experiencing low blood sugar may not be able to manage for themselves, take food or liquid orally or may be unconscious. Glucagon is a medication that reverses low blood sugar. Up until 2018, glucagon had to be reconstituted immediately before injection because of the medication’s lack of stability after reconstitution. A medication recently approved for patients 6 years through adult is Dasiglucagon. This form of glucagon comes in a ready-to-administer, pre-filled syringe, making it easier for caretakers and bystanders to administer in an emergency situation due to the readiness of the medication. PURPOSE: The purpose of the paper is to evaluate literature that pertains to the ease of use and patient safety of dasiglucagon HypoPal autoinjector for the management of severe hypoglycemia. |
format | Online Article Text |
id | pubmed-10473428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104734282023-09-02 Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia Schaumleffel, Carol Patient Prefer Adherence Review INTRODUCTION: Severe hypoglycemia is a medical emergency that must be treated promptly in order to prevent complications or death in a patient. Patients who have been diagnosed with Type 1 diabetes and treated with insulin have the potential to experience a severe hypoglycemia episode, or low blood sugar. When a patient is experiencing severe hypoglycemia, it is imperative for this patient to receive glucose quickly. However, patients who are experiencing low blood sugar may not be able to manage for themselves, take food or liquid orally or may be unconscious. Glucagon is a medication that reverses low blood sugar. Up until 2018, glucagon had to be reconstituted immediately before injection because of the medication’s lack of stability after reconstitution. A medication recently approved for patients 6 years through adult is Dasiglucagon. This form of glucagon comes in a ready-to-administer, pre-filled syringe, making it easier for caretakers and bystanders to administer in an emergency situation due to the readiness of the medication. PURPOSE: The purpose of the paper is to evaluate literature that pertains to the ease of use and patient safety of dasiglucagon HypoPal autoinjector for the management of severe hypoglycemia. Dove 2023-08-28 /pmc/articles/PMC10473428/ /pubmed/37663896 http://dx.doi.org/10.2147/PPA.S325865 Text en © 2023 Schaumleffel. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Schaumleffel, Carol Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia |
title | Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia |
title_full | Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia |
title_fullStr | Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia |
title_full_unstemmed | Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia |
title_short | Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia |
title_sort | evaluating ease of use and patient safety of dasiglucagon hypo pal autoinjector for the management of hypoglycemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473428/ https://www.ncbi.nlm.nih.gov/pubmed/37663896 http://dx.doi.org/10.2147/PPA.S325865 |
work_keys_str_mv | AT schaumleffelcarol evaluatingeaseofuseandpatientsafetyofdasiglucagonhypopalautoinjectorforthemanagementofhypoglycemia |